Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer

被引:46
作者
Brands, Maria T. [1 ]
Smeekens, Elisabeth A. J. [1 ]
Takes, Robert P. [2 ]
Kaanders, Johannes H. A. M. [3 ]
Verbeek, Andre L. M. [4 ]
Merkx, Matthias A. W. [1 ]
Geurts, Sandra M. E. [4 ]
机构
[1] Radboud Univ Nijmegen, Dept Oral & Maxillofacial Surg, Med Ctr, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Dept Ear Nose & Throat Surg, Med Ctr, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Dept Radiat Oncol, Med Ctr, Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands
关键词
head and neck cancer; oral cancer; postoperative surveillance; recurrence; routine follow-up; second primary tumor; SQUAMOUS-CELL CARCINOMA; ROUTINE FOLLOW-UP; UPPER AERODIGESTIVE TRACT; CURATIVE TREATMENT; SALVAGE TREATMENT; ADVANCED HEAD; NECK-CANCER; SURVIVAL; SURGERY; RISK;
D O I
10.1002/cam4.2124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Routine follow-up after curative treatment of patients with oral squamous cell carcinoma (OSCC) is common practice considering the high risk of second primaries and recurrences (ie second events). Current guidelines advocate a follow-up period of at least 5 years. The recommendations are not evidence-based and benefits are unclear. This is even more so for follow-up after a second event. To facilitate the development of an evidence- and personalized follow-up program for OSCC, we investigated the course of time until the second and subsequent events and studied the risk factors related to these events. Materials and methods We retrospectively studied 594 OSCC patients treated with curative intent at the Head and Neck Cancer Unit of the Radboud University Medical Centre from 2000 to 2012. Risk of recurrence was calculated addressing death from intercurrent diseases as competing event. Results The 1-, 5- and 10-year cumulative risks of a second event were 17% (95% CI:14%;20%), 30% (95% CI:26%;33%), and 37% (95% CI:32%;41%). Almost all locoregional recurrences occurred in the first 2 years after treatment. The incidence of second primary tumors was relatively stable over the years. The time pattern of presentation of third events was similar. Discussion Our findings support a follow-up time of 2 years after curative treatment for OSCC. Based on the risk of recurrence there is no indication for a different follow-up protocol after first and second events. After 2 years, follow-up should be tailored to the individual needs of patients for supportive care, and monitoring of late side-effects of treatment.
引用
收藏
页码:5810 / 5819
页数:10
相关论文
共 44 条
[1]   Factors Affecting Long-Term Survival in Patients with Recurrent Head and Neck Cancer May Help Define the Role of Post-Treatment Surveillance [J].
Agrawal, Amit ;
Hammond, Thomas H. ;
Young, Gregory S. ;
Avon, Amanda L. ;
Ozer, Enver ;
Schuller, David E. .
LARYNGOSCOPE, 2009, 119 (11) :2135-2140
[2]  
[Anonymous], 2016, NCCN Clin Pract Guidel Oncol
[3]   Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck - An analysis of two Eastern Cooperative Oncology Group randomized trials [J].
Argiris, A ;
Li, Y ;
Forastiere, A .
CANCER, 2004, 101 (10) :2222-2229
[4]   Tobacco smoking, smoking cessation, and cumulative risk of upper aerodigestive tract cancers [J].
Bosetti, Cristina ;
Gallus, Silvano ;
Peto, Richard ;
Negri, Eva ;
Talamini, Renato ;
Tavani, Alessandra ;
Franceschi, Silvia ;
La Vecchia, Carlo .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (04) :468-473
[5]   THE VALUE OF FOLLOW-UP IN PATIENTS TREATED FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BOYSEN, M ;
LOVDAL, O ;
TAUSJO, J ;
WINTHER, F .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :426-430
[6]   Follow-up after curative treatment for oral squamous cell carcinoma. A critical appraisal of the guidelines and a review of the literature [J].
Brands, M. T. ;
Brennan, P. A. ;
Verbeek, A. L. M. ;
Merkx, M. A. W. ;
Geurts, S. M. E. .
EJSO, 2018, 44 (05) :559-565
[7]  
Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167
[8]   Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer? [J].
Cooney, TR ;
Poulsen, MG .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1999, 125 (04) :379-382
[9]   Cumulative incidence estimation in the presence of competing risks [J].
Coviello, Vincenzo ;
Boggess, May .
STATA JOURNAL, 2004, 4 (02) :103-112
[10]  
CRAWFORD B, 2013, PATIENT SURVEILLANCE